Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Prevalence of comorbid substance use disorder during long-term central stimulant treatment in adult ADHD.

Torgersen T, Gjervan B, Rasmussen K, Vaaler A, Nordahl HM.

Atten Defic Hyperact Disord. 2013 Mar;5(1):59-67. doi: 10.1007/s12402-012-0094-2.

PMID:
23104523
2.

Predictive factors for more than 3 years' duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: a retrospective, naturalistic study.

Torgersen T, Gjervan B, Nordahl HM, Rasmussen K.

J Clin Psychopharmacol. 2012 Oct;32(5):645-52. doi: 10.1097/JCP.0b013e3182664dbc.

PMID:
22926598
3.
4.

A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.

Kollins SH.

Curr Med Res Opin. 2008 May;24(5):1345-57. doi: 10.1185/030079908X280707 . Review.

PMID:
18384709
5.
6.

Comorbid attention deficit/hyperactivity disorder and substance use disorder: treatment considerations.

Klassen LJ, Bilkey TS, Katzman MA, Chokka P.

Curr Drug Abuse Rev. 2012 Sep;5(3):190-8. Review.

PMID:
22571450
7.

Methylphenidate in Adults with Attention Deficit Hyperactivity Disorder and Substance Use Disorders.

Simon N, Rolland B, Karila L.

Curr Pharm Des. 2015;21(23):3359-66. Review.

PMID:
26088112
8.

Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis.

van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W, Smit F, Crunelle CL, Swets M, Schoevers RA.

Drug Alcohol Depend. 2012 Apr 1;122(1-2):11-9. doi: 10.1016/j.drugalcdep.2011.12.007.

PMID:
22209385
9.

Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.

Molina BS, Hinshaw SP, Eugene Arnold L, Swanson JM, Pelham WE, Hechtman L, Hoza B, Epstein JN, Wigal T, Abikoff HB, Greenhill LL, Jensen PS, Wells KC, Vitiello B, Gibbons RD, Howard A, Houck PR, Hur K, Lu B, Marcus S; MTA Cooperative Group..

J Am Acad Child Adolesc Psychiatry. 2013 Mar;52(3):250-63. doi: 10.1016/j.jaac.2012.12.014.

10.
11.

Screening and imputed prevalence of ADHD in adult patients with comorbid substance use disorder at a residential treatment facility.

Adler LA, Guida F, Irons S, Rotrosen J, O'Donnell K.

Postgrad Med. 2009 Sep;121(5):7-10. doi: 10.3810/pgm.2009.09.2047.

PMID:
19820269
12.

Factors associated with a positive occupational outcome during long-term central stimulant treatment in adult ADHD.

Torgersen T, Krokstad S, Vaaler AE.

Atten Defic Hyperact Disord. 2014 Dec;6(4):281-90. doi: 10.1007/s12402-014-0135-0.

PMID:
24700330
13.

[Substance use disorders and ADHD: an overview of recent Dutch research].

van Emmerik-van Oortmerssen K, Crunelle CL, Carpentier PJ.

Tijdschr Psychiatr. 2013;55(11):861-6. Review. Dutch.

14.

Substance abuse in patients with attention-deficit/hyperactivity disorder.

Bukstein O.

Medscape J Med. 2008 Jan 31;10(1):24. Review.

15.

Impact of substance use disorder on ADHD and its treatment.

Wilens TE, Upadhyaya HP.

J Clin Psychiatry. 2007 Aug;68(8):e20. Review.

16.

A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults.

Faraone SV, Biederman J, Wilens TE, Adamson J.

Psychol Med. 2007 Dec;37(12):1743-52.

PMID:
17349106
17.

Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder.

Biederman J, Wilens T, Mick E, Spencer T, Faraone SV.

Pediatrics. 1999 Aug;104(2):e20.

PMID:
10429138
18.

[Methylphenidate. Therapy option for adults with ADHD and comorbid substance use disorder?].

Paslakis G, Kiefer F, Diehl A, Alm B, Sobanski E.

Nervenarzt. 2010 Mar;81(3):277-88. doi: 10.1007/s00115-009-2916-9. Review. German.

PMID:
20108084
19.

When ADHD and substance use disorders intersect: relationship and treatment implications.

Wilens TE, Fusillo S.

Curr Psychiatry Rep. 2007 Oct;9(5):408-14. Review.

PMID:
17915081
20.

Substance use disorders in association with attention-deficit/hyperactivity disorder, co-morbid mental disorders, and medication in a nationwide sample.

Steinhausen HC, Bisgaard C.

Eur Neuropsychopharmacol. 2014 Feb;24(2):232-41. doi: 10.1016/j.euroneuro.2013.11.003.

PMID:
24314850
Items per page

Supplemental Content

Support Center